FOI 6507 – Q2

|  |  |
| --- | --- |
| **Treatment** | **Patients in last 3 months** |
| Bortezomib [Velcade] and Dexamethasone  |   |
| Bortezomib [Velcade], Thalidomide and Dexamethasone [known as VTD]  |   |
| Bortezomib [Velcade], Cyclophosphamide/Melphalan and Dexamethasone/Prednisolone [known as VCD or VMP]  |   |
| Lenalidomide [Revlimid] monotherapy   |   |
| Lenalidomide [Revlimid] and Dexamethasone   |   |
| Lenalidomide [Revlimid], Bortezomib [Velcade] and Dexamethasone   |   |
| Lenalidomide [Revlimid], Melphalan and Prednisolone  |   |
| Thalidomide, Cyclophosphamide/Melphalan, and Dexamethasone/Prednisolone [known as MPT or CTD]  |   |
| Bortezomib [Velcade] monotherapy  |   |
| Carfilzomib [Kyprolis] and Dexamethasone  |   |
| Carfilzomib [Kyprolis], Lenalidomide [Revlimid], and Dexamethasone [known as KRD]  |   |
| Daratumumab [Darzalex], Velcade [Bortezomib] and Dexamethasone [known as DVD]  |   |
| Daratumumab [Darzalex], Velcade [Botezomib], Thalidomide and Dexamethasone [known as Dara-VTd] |   |
| Daratumumab [Darzalex], Lenalidomide [Revlimid] and Dexamethasone   |   |
| Daratumumab [Darzalex], Pomalidomide [Imnovid] and Dexamethasone (DaraPd) |   |
| Daratumumab [Darzalex] monotherapy   |   |
| Isatuximab [Sarclisa], Pomalidomide [Imnovid] and Dexamethasone [known as IsaPd] |   |
| Isatuximab [Sarclisa], Carfilzomib [Kyprolis] and Dexamethasone [known as IsaKd] |   |
| Ixazomib [Ninlaro], Lenalidomide [Revlimid] and Dexamethasone [known as IRD]  |   |
| Pomalidomide [Imnovid] and Dexamethasone  |   |
| Panobinostat [Farydak], Bortezomib [Velcade] and Dexamethasone   |   |
| Any other systemic anti-cancer treatment |   |